Ignite Creation Date:
2024-05-06 @ 4:28 PM
Last Modification Date:
2024-10-26 @ 2:10 PM
Study NCT ID:
NCT04993677
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-20
First Post:
2021-07-30
Brief Title:
A Study of SEA-CD40 Given With Other Drugs in Cancers
Sponsor:
Seagen Inc
Organization:
Seagen Inc
Study Overview
Official Title:
An Open-label Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is being done to see if an experimental drug SEA-CD40 works when its given with other cancer drugs to treat some types of cancer It will also study side effects from the drug
There are 2 parts in this trial In one part participants have melanoma that has come back after treatment or cant be removed by surgery Participants in this part will get SEA-CD40 and pembrolizumab In the other part participants have non-small cell lung cancer NSCLC that has spread through their body These participants will get SEA-CD40 pembrolizumab carboplatin and pemetrexed
There are 2 parts in this trial In one part participants have melanoma that has come back after treatment or cant be removed by surgery Participants in this part will get SEA-CD40 and pembrolizumab In the other part participants have non-small cell lung cancer NSCLC that has spread through their body These participants will get SEA-CD40 pembrolizumab carboplatin and pemetrexed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| KEYNOTE-C86 | OTHER | Merck Sharp Dohme Corp | None |